Literature DB >> 20614847

Anti-Tribbles homolog 2 autoantibodies in Japanese patients with narcolepsy.

Hiromi Toyoda1, Susumu Tanaka, Taku Miyagawa, Yutaka Honda, Katsushi Tokunaga, Makoto Honda.   

Abstract

STUDY
OBJECTIVES: Narcolepsy is a sleep disorder characterized by excessive daytime sleepiness and cataplexy. The association with human leukocyte antigen (HLA)-DQB1*0602 and T-cell receptor alpha locus suggests that autoimmunity plays a role in narcolepsy. A recent study reported an increased prevalence of autoantibodies against Tribbles homolog 2 (TRIB2) in patients with narcolepsy. To replicate this finding, we examined anti-TRIB2 autoantibodies in Japanese patients with narcolepsy.
DESIGN: We examined anti-TRIB2 autoantibodies against a full-length [35S]-labeled TRIB2 antigen in Japanese patients with narcolepsy-cataplexy (n = 88), narcolepsy without cataplexy (n = 18), and idiopathic hypersomnia with long sleep time (n = 11). The results were compared to Japanese healthy controls (n = 87). Thirty-seven healthy control subjects were positive for HLA-DRB1*1501-DQB1*0602. We also examined autoantibodies against another Tribbles homolog, TRIB3, as an experimental control. MEASUREMENTS AND
RESULTS: Autoantibodies against TRIB2 were found in 26.1% of patients with narcolepsy-cataplexy, a significantly higher prevalence than the 2.3% in healthy controls. We found that anti-TRIB3 autoantibodies were rare in patients with narcolepsy and showed no association with anti-TRIB2 indices. No significant correlation was found between anti-TRIB2 positivity and clinical information.
CONCLUSIONS: We confirmed the higher prevalence and specificity of anti-TRIB2 autoantibodies in Japanese patients with narcolepsy-cataplexy. This suggests a subgroup within narcolepsy-cataplexy might be affected by an anti-TRIB2 autoantibody-mediated autoimmune mechanism.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20614847      PMCID: PMC2894429          DOI: 10.1093/sleep/33.7.875

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  15 in total

1.  The frustrating and mostly fruitless search for an autoimmune cause of narcolepsy.

Authors:  Thomas E Scammell
Journal:  Sleep       Date:  2006-05       Impact factor: 5.849

2.  Anti-CYP2D6 antibodies detected by quantitative radioligand assay and relation to antibodies to liver-specific arginase in patients with autoimmune hepatitis.

Authors:  Masahiro Kimura; Ke-ita Tatsumi; Hisato Tada; Yukiko Izumi; Akira Kaneko; Michio Kato; Manabu Masuzawa; Masaki Ikemoto; Yoshiyasu Yabusaki; Yoh Hidaka; Nobuyuki Amino
Journal:  Clin Chim Acta       Date:  2002-02       Impact factor: 3.786

3.  Hypocretin (orexin) deficiency in human narcolepsy.

Authors:  S Nishino; B Ripley; S Overeem; G J Lammers; E Mignot
Journal:  Lancet       Date:  2000-01-01       Impact factor: 79.321

4.  Detection of autoantibodies against hypocretin, hcrtrl, and hcrtr2 in narcolepsy: anti-Hcrt system antibody in narcolepsy.

Authors:  Susumu Tanaka; Yutaka Honda; Yuichi Inoue; Makoto Honda
Journal:  Sleep       Date:  2006-05       Impact factor: 5.849

5.  Identification of tribbles homolog 2 as an autoantigen in autoimmune uveitis by phage display.

Authors:  Yujin Zhang; Janet L Davis; Wei Li
Journal:  Mol Immunol       Date:  2005-02-08       Impact factor: 4.407

6.  A novel assay for detecting antibodies to cytochrome P4502D6, the molecular target of liver kidney microsomal antibody type 1.

Authors:  N Kerkar; Y Ma; M Hussain; L Muratori; C Targett; R Williams; F B Bianchi; G Mieli-Vergani; D Vergani
Journal:  J Immunol Methods       Date:  1999-03-04       Impact factor: 2.303

7.  A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains.

Authors:  C Peyron; J Faraco; W Rogers; B Ripley; S Overeem; Y Charnay; S Nevsimalova; M Aldrich; D Reynolds; R Albin; R Li; M Hungs; M Pedrazzoli; M Padigaru; M Kucherlapati; J Fan; R Maki; G J Lammers; C Bouras; R Kucherlapati; S Nishino; E Mignot
Journal:  Nat Med       Date:  2000-09       Impact factor: 53.440

8.  The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias.

Authors:  Emmanuel Mignot; Gert Jan Lammers; Beth Ripley; Michele Okun; Sonia Nevsimalova; Sebastiaan Overeem; Jitka Vankova; Jed Black; John Harsh; Claudio Bassetti; Harald Schrader; Seiji Nishino
Journal:  Arch Neurol       Date:  2002-10

9.  Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups.

Authors:  E Mignot; L Lin; W Rogers; Y Honda; X Qiu; X Lin; M Okun; H Hohjoh; T Miki; S Hsu; M Leffell; F Grumet; M Fernandez-Vina; M Honda; N Risch
Journal:  Am J Hum Genet       Date:  2001-02-13       Impact factor: 11.025

10.  Reduced number of hypocretin neurons in human narcolepsy.

Authors:  T C Thannickal; R Y Moore; R Nienhuis; L Ramanathan; S Gulyani; M Aldrich; M Cornford; J M Siegel
Journal:  Neuron       Date:  2000-09       Impact factor: 17.173

View more
  31 in total

1.  The trouble with Tribbles: do antibodies against TRIB2 cause narcolepsy?

Authors:  Andrew S P Lim; Thomas E Scammell
Journal:  Sleep       Date:  2010-07       Impact factor: 5.849

2.  Post-H1N1 narcolepsy-cataplexy.

Authors:  Yves Dauvilliers; Jacques Montplaisir; Valéerie Cochen; Alex Desautels; Mali Einen; Ling Lin; Minae Kawashima; Sophie Bayard; Christelle Monaca; Michel Tiberge; Daniel Filipini; Asit Tripathy; Bich Hong Nguyen; Suresh Kotagal; Emmanuel Mignot
Journal:  Sleep       Date:  2010-11       Impact factor: 5.849

3.  Translational profiling of hypocretin neurons identifies candidate molecules for sleep regulation.

Authors:  Jasbir Dalal; Jee Hoon Roh; Susan E Maloney; Afua Akuffo; Samir Shah; Han Yuan; Brie Wamsley; Wendell B Jones; Cristina de Guzman Strong; Paul A Gray; David M Holtzman; Nathaniel Heintz; Joseph D Dougherty
Journal:  Genes Dev       Date:  2013-02-21       Impact factor: 11.361

4.  Is it Time for Immunotherapy Trials in Narcolepsy?

Authors:  Andreas Lutterotti
Journal:  J Clin Sleep Med       Date:  2017-03-15       Impact factor: 4.062

5.  T cells in patients with narcolepsy target self-antigens of hypocretin neurons.

Authors:  Daniela Latorre; Ulf Kallweit; Eric Armentani; Mathilde Foglierini; Federico Mele; Antonino Cassotta; Sandra Jovic; David Jarrossay; Johannes Mathis; Francesco Zellini; Burkhard Becher; Antonio Lanzavecchia; Ramin Khatami; Mauro Manconi; Mehdi Tafti; Claudio L Bassetti; Federica Sallusto
Journal:  Nature       Date:  2018-09-19       Impact factor: 49.962

Review 6.  Control of sleep and wakefulness.

Authors:  Ritchie E Brown; Radhika Basheer; James T McKenna; Robert E Strecker; Robert W McCarley
Journal:  Physiol Rev       Date:  2012-07       Impact factor: 37.312

7.  Narcolepsy in the pediatric population.

Authors:  Erick N Viorritto; Suraiya A Kureshi; Judith A Owens
Journal:  Curr Neurol Neurosci Rep       Date:  2012-04       Impact factor: 5.081

8.  Intravenous Immunoglobulin Therapy in Pediatric Narcolepsy: A Nonrandomized, Open-Label, Controlled, Longitudinal Observational Study.

Authors:  Michel Lecendreux; Johanna Berthier; Jennifer Corny; Olivier Bourdon; Claire Dossier; Christophe Delclaux
Journal:  J Clin Sleep Med       Date:  2017-03-15       Impact factor: 4.062

Review 9.  Narcolepsy Type 1 as an Autoimmune Disorder: Evidence, and Implications for Pharmacological Treatment.

Authors:  Lucie Barateau; Roland Liblau; Christelle Peyron; Yves Dauvilliers
Journal:  CNS Drugs       Date:  2017-10       Impact factor: 5.749

10.  Narcolepsy: clinical differences and association with other sleep disorders in different age groups.

Authors:  Sona Nevsimalova; Juraj Pisko; Jitka Buskova; David Kemlink; Iva Prihodova; Karel Sonka; Jelena Skibova
Journal:  J Neurol       Date:  2012-10-16       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.